3- (2- ethylphenyl)- 5- (3- methoxyphenyl)- 1H- 1,2,4- triazole

Subscribe to Selected New Research on 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole

9 relevant articles (1 outcomes, 2 trials/studies) found for this Bio-Agent

Description: non-hormonal antifertility agent; RN & N1 from CA Vol 90

Also Known As:

DL 111; DL 111-IT; DL-111; DL111-IT; L 14111; L-14111; ST1959; contragestazol; 1H-1,2,4-triazole, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Triazoles: 104

3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole: 9

Experts

1.	Yang, Bo: 2 articles (01/2006 - 12/2005)
2.	Zhu, Dan-yan: 1 article (01/2006)
3.	He, Qiao-jun: 1 article (01/2006)
4.	Fang, Rui-ying: 1 article (01/2006)
5.	Lou, Yi-jia: 1 article (01/2006)
6.	Fang, Rui-Ying: 1 article (12/2005)
7.	He, Qiao-Jun: 1 article (12/2005)
8.	Lou, Yi-Jia: 1 article (12/2005)
9.	Ursillo, Angela: 1 article (06/2004)
10.	Stasi, Maria Antonietta: 1 article (06/2004)

Related Diseases

1.	Inflammation 06/28/2004 - "The therapeutic efficacy of the immunomodulator 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole (ST1959) in colonic inflammation was assessed in rats" Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 01/01/2006 - "CONCLUSIONS: DL111-IT could inhibit the proliferation of cancer cells both in vitro and in vivo via a cell cycle regulation pathway." 01/01/2006 - "RESULTS: DL111-IT exhibited high efficiency on cell growth inhibition of 12 cancer cell lines, the IC50 values were 4.1-19.7 microg/ml. In Sarcoma-180 (S180) and Hepatoma-22 (H22) tumor bearing mice models, the inhibition rates were 55.9 and 55.6%, respectively, at the doses of DL111-IT 12.5-50.0 mg/kg for 9 days consecutive administration" 01/01/2006 - "Antiproliferative activity of contragestazol (DL111-IT) in murine and human tumor models in vitro and in vivo." 12/01/2005 - "The drug concentration that yielded 50% cell inhibition (IC50 value) was 9.9 mg/mL. In the PC3 tumor xenograft study, DL111-IT (1.25 mg/kg-20.0 mg/kg) given once a day for 10 days significantly inhibited tumor growth, with the inhibition rate ranging from 21% to 50%" 12/01/2005 - "METHODS: The cell killing ability of DL111-IT was measured by the 3-(4,5-dimethylthia-zol,2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent assay method and the tumor xenograft model" Get all the results and reference details, order at left...
3.	Carcinoma (Carcinomatosis) 01/01/2006 - "Human ovarian carcinoma (HO-8910) xenograft study showed that, nine administrations (within 15 days) of DL111-IT (12.5-50.0 mg/kg) significantly inhibited tumor growth with the inhibition rates ranging from 17.0 to 64.3%" Get all the results and reference details, order at left...
4.	Anemia 10/01/2004 - "A retrospective study comparing 2 groups of pregnant women: 111 (pregnant women) with anemia (Hb < 8 g/dl), 111 non- anemic pregnant women (Hb >10 g/dl)" 07/15/2008 - "Moreover, ST1959 treatment significantly counteracted GVHD-induced normocitic anemia by increasing hemoglobin, hematocrit, platelet, and red and white blood cell counts" Get all the results and reference details, order at left...
5.	Wounds and Injuries (Trauma) 05/01/2001 - "The data verified that the decrease in uterine polyamine levels and subsequent decidual cells injuries were the critical role of early pregnancy arrest induced by DL111-IT or RU486" Get all the results and reference details, order at left...
12 Diseases and 9 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	3- (2- ethylphenyl)- 5- (3- methoxyphenyl)- 1H- 1,2,4- triazole
2.	Mifepristone (RU 486)
3.	Cyclin D1
4.	Trypan Blue
5.	Peroxidase (Myeloperoxidase)
6.	Interferon Type II (Interferon, gamma)
7.	Hemoglobins (Hemoglobin)
7 Drugs and Important Bio-Agents and 6 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>